{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06257264",
            "orgStudyIdInfo": {
                "id": "BG-68501-101"
            },
            "organization": {
                "fullName": "BeiGene",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors",
            "officialTitle": "A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-examine-the-safety-of-different-doses-of-bg-given-to-participants-with-advanced-stage-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-05",
            "studyFirstSubmitQcDate": "2024-02-05",
            "studyFirstPostDateStruct": {
                "date": "2024-02-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BeiGene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors. The study will also identify a recommended dose for expansion (RDFE) in subsequent disease directed studies.\n\nThe study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion) and Part 2 (dose expansion)."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Small Cell Lung Cancer",
                "Ovarian Cancer",
                "Gastric Cancer",
                "Hormone-receptor-positive Breast Cancer",
                "Hormone Receptor Positive HER-2 Negative Breast Cancer",
                "Advanced Solid Tumor",
                "Endometrial Cancer",
                "Prostate Cancer"
            ],
            "keywords": [
                "breast cancer",
                "small cell lung cancer",
                "ovarian cancer",
                "gastric cancer",
                "cdk2 inhibitor",
                "BG-68501",
                "HR+ HER2- breast cancer",
                "endometrial cancer",
                "prostate cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 108,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Dose Escalation and Safety Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Sequential cohorts of increasing dose levels of BG-68501 will be evaluated as monotherapy and in combination with fulvestrant.",
                    "interventionNames": [
                        "Drug: BG-68501",
                        "Drug: Fulvestrant"
                    ]
                },
                {
                    "label": "Part 2: Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "The RFDE for BG-68501 (as monotherapy and in combination with fulvestrant) from Part 1 will be evaluated in selected tumor cohorts.",
                    "interventionNames": [
                        "Drug: BG-68501",
                        "Drug: Fulvestrant"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BG-68501",
                    "description": "Planned doses administered orally.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation and Safety Expansion",
                        "Part 2: Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fulvestrant",
                    "description": "Standard dose administered via intramuscular injection.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation and Safety Expansion",
                        "Part 2: Dose Expansion"
                    ],
                    "otherNames": [
                        "Faslodex\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "Number of participants with treatment-emergent AEs and SAEs.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Part 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-68501",
                    "description": "MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate. MAD is defined as the highest dose administered if MTD is not reached.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Part 1: Recommended dose(s) for Expansion (RDFE) of BG-68501 in participants with solid tumors",
                    "description": "RDFE of BG-68501 alone will be determined based upon the MTD or MAD.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Part 1: RDFE of BG-68501 and fulvestrant in participants with hormone-receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer",
                    "description": "RDFE of BG-68501 in combination with fulvestrant will be determined based upon the MTD or MAD.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Part 2: Objective Response Rate",
                    "description": "ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). CR and PR that is confirmed by repeat assessments, as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",
                    "timeFrame": "Up to approximately 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1: ORR",
                    "description": "ORR is defined as the percentage of participants with best overall response of CR or PR. CR and PR that is confirmed by repeat assessments, as assessed by the investigator using RECIST v1.1.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Part 2: Number of participants with AEs and SAEs",
                    "description": "Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Parts 1 and 2: Duration of Response (DOR)",
                    "description": "DOR is defined as the time from the first confirmed objective response by the investigator using RECIST v1.1 until the first documentation of disease progression after treatment initiation or death, whichever comes first.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Parts 1 and 2: Time to Response (TTR)",
                    "description": "TTR is defined as the time from the treatment initiation to the first determination of overall response by the investigator using RECIST v1.1.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Parts 1 and 2: Disease Control Rate (DCR)",
                    "description": "DCR is defined as the percentage of participants with the best overall response, of a CR, PR, and stable disease assessed by the investigator using RECIST v1.1.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Parts 1 and 2: Clinical Benefit Rate (CBR)",
                    "description": "CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting \u2265 24 weeks.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Part 1: Maximum observed plasma concentration (Cmax) for BG-68501",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Part 1: Observed plasma trough concentration (Ctrough) for BG-68501",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Part 1: Area under the concentration-time curve (AUC) for BG-68501",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Part 1: Half-life (t1/2) for BG-68501",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Part 2: Plasma concentrations for BG-68501",
                    "timeFrame": "From Cycle 1 Day 1 up to Cycle 5 Day 1 (each cycle is 28 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "General Inclusion Criteria:\n\n* Female participants with advanced or metastatic HR+/HER2- breast cancer will be required to have ovarian function suppression using gonadotropin hormone-releasing hormone (GnRH) agonists (such as goserelin) or be postmenopausal.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1.\n* Adequate organ function.\n\nPart 1 (Dose Escalation) Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed advanced or metastatic solid tumors potentially associated with CDK2 dependency including HR+/HER2- breast cancer, platinum refractory or resistant serous ovarian, fallopian tube, primary peritoneal cancer (PROC), small cell lung cancer (SCLC), and others.\n* Participants should have received prior available systemic therapy for their condition and should be refractory to or intolerant of standard-of-care therapies.\n* Participants with advanced solid tumors must have measurable disease per RECIST 1.1.\n\nPart 1 (Safety Expansion) Inclusion Criteria:\n\n* Participants with advanced or metastatic HR+/HER2- breast cancer, PROC, or SCLC.\n\nPart 2 (Dose Expansion) Inclusion Criteria:\n\n* Participants with selected advanced or metastatic HR+/HER2- breast cancer, PROC, SCLC, or advanced solid tumors with a specific gene mutation based on standard-of-care testing.\n\nGeneral Exclusion Criteria:\n\n* Prior therapy selectively targeting CDK2 inhibition. Prior CDK4/6 inhibitor therapy is permitted and required in local regions where it is approved and available.\n* Known leptomeningeal disease or uncontrolled, untreated brain metastasis. Participants with a history of treated central nervous system (CNS) metastases may be eligible if they meet additional criteria.\n* Any malignancy \u2264 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).\n* Uncontrolled diabetes.\n* Infection requiring systemic antibacterial, antifungal, or antiviral therapy antiviral therapy \u2264 28 days before the first dose of study drug(s), or symptomatic COVID-19 infection.\n* History of hepatitis B or active hepatitis C infection.\n* Any major surgical procedure \u2264 28 days before the first dose of study treatment(s).\n* Prior allogeneic stem cell transplantation, or organ transplantation.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Director",
                    "role": "CONTACT",
                    "phone": "1.877.828.5568",
                    "email": "clinicaltrials@beigene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "BeiGene",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Florida Cancer Specialists and Research Institute",
                    "status": "RECRUITING",
                    "city": "Lake Mary",
                    "state": "Florida",
                    "zip": "32746",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.75888,
                        "lon": -81.31784
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Titan Health Partners Llc Dba Astera Cancer Care",
                    "status": "RECRUITING",
                    "city": "East Brunswick",
                    "state": "New Jersey",
                    "zip": "08816",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.42788,
                        "lon": -74.41598
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Blacktown Cancer and Haematology Centre",
                    "status": "RECRUITING",
                    "city": "Blacktown",
                    "state": "New South Wales",
                    "zip": "2148",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.76667,
                        "lon": 150.91667
                    }
                },
                {
                    "facility": "Genesiscare North Shore",
                    "status": "RECRUITING",
                    "city": "St Leonards",
                    "state": "New South Wales",
                    "zip": "2065",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.82344,
                        "lon": 151.19836
                    }
                },
                {
                    "facility": "Cancer Research South Australia",
                    "status": "RECRUITING",
                    "city": "Adelaide",
                    "state": "South Australia",
                    "zip": "5000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                },
                {
                    "facility": "Monash Health",
                    "status": "RECRUITING",
                    "city": "Clayton",
                    "state": "Victoria",
                    "zip": "3168",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                },
                {
                    "id": "D000010051",
                    "term": "Ovarian Neoplasms"
                },
                {
                    "id": "D000013274",
                    "term": "Stomach Neoplasms"
                },
                {
                    "id": "D000055752",
                    "term": "Small Cell Lung Carcinoma"
                },
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000010049",
                    "term": "Ovarian Diseases"
                },
                {
                    "id": "D000000291",
                    "term": "Adnexal Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000013272",
                    "term": "Stomach Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M28323",
                    "name": "Small Cell Lung Carcinoma",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "asFound": "Gastric Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12972",
                    "name": "Ovarian Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3643",
                    "name": "Adnexal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16062",
                    "name": "Stomach Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5271",
                    "name": "Small Cell Lung Cancer",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077267",
                    "term": "Fulvestrant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000065171",
                    "term": "Estrogen Receptor Antagonists"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1723",
                    "name": "Fulvestrant",
                    "asFound": "Challenge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}